TD Cowen raised the firm’s price target on Acadia Pharmaceuticals to $35 from $28 and keeps an Outperform rating on the shares. The firm noted they preannounced Daybue net sales of $21-23M and 3Q guidance of $45-55M, beating consensus and our 2Q estimates. We are amazed at Daybue’s early sales and believe it will continue to outperform.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $33 from $28 at H.C. Wainwright
- Acadia Pharmaceuticals price target raised to $23 from $20 at Oppenheimer
- Acadia Pharmaceuticals price target raised to $39 from $31 at JMP Securities
- Here’s Why Acadia (NASDAQ:ACAD) Stock Shot Up 23% Yesterday
- Acadia acquires ex-North American rights to trofinetide